What Actually Is BMAC? Let Me Be Honest With You First

Patients come to me having read about BMAC online — and half of them arrive with wild expectations, and the other half with wild fears. Some think I am going to inject magical stem cells that will regrow their knee cartilage overnight. Others are convinced it is some experimental, illegal procedure borrowed from science fiction. The truth, as with most things in medicine, sits somewhere more nuanced and — actually — more interesting than either of those stories.

BMAC stands for Bone Marrow Aspirate Concentrate. At its most basic, it is this: we take a small amount of your own bone marrow, typically from the back of your pelvic bone, spin it in a specialised centrifuge to concentrate the most valuable cellular components, and then inject that concentrate directly into the area that needs healing — a joint, a tendon, a necrotic bone. Same day. Your own tissue. No donors. No genetic modification. No laboratory culture.

That is the procedure in one paragraph. But what makes it remarkable — and why it has become one of the most actively researched areas in regenerative pain medicine — is what those concentrated cells actually do once they arrive at the target tissue.

The Cells Inside BMAC — What Is Actually Being Injected

This is the part of any BMAC consultation I spend the most time on. Because the term "stem cells" gets thrown around loosely — by clinics, by patients who have googled, and frankly by some doctors who should know better. So let us be precise.

When bone marrow is aspirated and concentrated, you get a heterogeneous mixture of nucleated cells. Nucleated simply means cells with an intact nucleus — as opposed to red blood cells, which lose their nucleus at maturity. The key populations in BMAC include:

Mesenchymal Stromal Cells (MSCs)

These are the cells that everybody is really talking about when they say "stem cells" in the orthopaedic or pain context. MSCs have the ability to differentiate — under the right conditions — into bone cells (osteoblasts), cartilage cells (chondrocytes), fat cells (adipocytes), and muscle cells. Critically, they also secrete a rich cocktail of growth factors and cytokines. In raw bone marrow, MSCs are present at roughly 0.001–0.01% of all nucleated cells — an extraordinarily low concentration. Concentrating the aspirate raises this, but BMAC is not a pure MSC product. This matters hugely from a regulatory standpoint, as I will explain shortly.

Haematopoietic Stem and Progenitor Cells

These are the cells responsible for generating blood cell lines. While not directly involved in orthopaedic regeneration, they contribute to the immune-modulatory environment post-injection, helping to damp down the local inflammatory response.

Platelets and Growth Factors

BMAC concentrate is platelet-rich. These platelets carry growth factors — PDGF, TGF-β, VEGF, IGF-1 — that directly stimulate tissue repair. In this sense, BMAC already has PRP-like properties built in, which is one reason even standalone BMAC can produce meaningful results.

Cytokines and Bioactive Proteins

The aspirate contains a symphony of interleukins and other signalling proteins — some anti-inflammatory, some pro-regenerative — that help modulate the local tissue environment. In an arthritic joint, for instance, BMAC can reduce the levels of destructive metalloproteinases and inflammatory cytokines that are slowly eating away at cartilage.

Where the Bone Marrow Comes From — The Harvest Technique

The posterior iliac crest — the curved ridge at the back of your hip bone — is the workhorse site for BMAC harvesting, and for good reason. It is easily accessible, yields the highest density of progenitor cells in the adult skeleton, and carries minimal morbidity when handled properly.

The procedure begins with the patient lying prone or in a lateral decubitus position. The skin and periosteum over the iliac crest is infiltrated with local anaesthetic — this is the most uncomfortable part, honestly, the pressure sensation of the needle entering bone. A large-bore harvest needle (typically 8–11 gauge) is then inserted through a small stab incision into the medullary cavity of the iliac bone. Bone marrow is aspirated in multiple small aliquots — usually 2–3 ml per pull, from different depths and angles — to maximise cellular diversity and avoid dilution with peripheral blood. Total aspirate volume is typically 40–80 ml.

The aspirate is then transferred to a dedicated processing kit and centrifuged in a closed, point-of-care system — the Arthrex Angel, the Harvest SmartPReP, or similar platforms are common. Centrifugation separates the cellular layers by density, allowing selective concentration of the nucleated cell-rich fraction. The result is 6–10 ml of BMAC that is then drawn into syringes for injection.

Alternative Harvest Sites

The anterior iliac crest can also be used — useful when the patient cannot tolerate prone positioning. Tibial and calcaneal marrow has been used in foot and ankle applications. The iliac crest remains standard because of its superior yield.

Why Not Call It Stem Cell Therapy? The Legal and Scientific Truth

I want to be very direct about this, because it matters — clinically, ethically, and legally. BMAC is not the same as stem cell therapy, even though it contains cells with stem-cell-like properties. The distinction is not just semantic. It is the difference between what you can legally and ethically do in a clinic today and what requires regulatory approval.

Mesenchymal stromal cells (MSCs) in BMAC are present at very low concentrations and are not culture-expanded — they are used exactly as nature intended, in their native marrow environment, with their supporting cell populations and signalling molecules intact. The moment you take those cells out, grow them in a laboratory for two to four weeks, expand them to millions, and re-infuse them — that is stem cell therapy. That is a drug in the regulatory sense, and in India, that requires CDSCO approval.

The Legal Position in India

The regulatory landscape in India has been in evolution. The ICMR and DBT established stem cell guidelines in 2007, with revisions in 2017 through the National Guidelines for Stem Cell Research (NGSCR). Importantly, the two-tier oversight structure — the IC-SCR and NAC-SCRT — was dissolved in March 2024, creating a regulatory transition period. Under the Drugs & Cosmetics Act 1940 as applied to cellular therapies: minimally manipulated, autologous, same-day, homologous use is generally permissible without CDSCO drug approval. This is the category BMAC falls into. Cells that are substantially manipulated — culture-expanded, genetically modified, combined with biomaterials for non-homologous use — are regulated as drugs and require full regulatory clearance.

So when I perform BMAC at IBAP Clinics, I am working within this framework: autologous (your own cells), minimally manipulated (concentrated but not cultured), same-day (no storage or banking), and homologous (bone marrow cells being used for bone and connective tissue indications). This is the ethical safe harbour.

The Position in the USA

In the United States, the FDA classifies human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. Same-day, minimally manipulated, autologous BMAC generally qualifies for a Section 361 exemption — meaning it does not require pre-market approval. Cultured, expanded, or allogeneic cell products require an Investigational New Drug (IND) application and full clinical trial approval. Many US orthopaedic and sports medicine practitioners routinely use point-of-care BMAC under this framework.

Cartilage Regeneration — The Honest Conversation

Cartilage is notoriously bad at healing itself. It has no blood supply, no nerve supply, and very few resident cells. Once it is damaged or worn away, the body struggles enormously to replace it. This is why joint replacement surgery has become so common — once cartilage is gone beyond a certain threshold, there are limited options. BMAC is the most compelling biological strategy we currently have for addressing early-to-moderate cartilage loss. And I will be careful to say "addressing" rather than "reversing," because that is a more honest word.

What BMAC does to cartilage — specifically in knee osteoarthritis, which has the largest evidence base — is reduce the inflammatory cytokine load that accelerates cartilage breakdown, provide MSC-derived signals that can stimulate chondrocyte activity, and improve the subchondral bone environment that cartilage sits upon. Several studies have now shown MRI-measurable improvements in cartilage thickness and quality at the 12–24 month mark. The 2025 narrative review in a peer-reviewed journal (PMC12113016) affirmed BMAC's promise for cartilage repair and subchondral bone remodelling, though it rightly called for larger randomised controlled trials. A 2024 four-year follow-up study on KL Grade III–IV knee OA (Nature Scientific Reports, Graz) showed sustained pain reduction and functional improvement — not perfect cartilage, but meaningful preservation and symptom relief.

The critical caveat: the window for BMAC benefit is earlier disease. Grade IV osteoarthritis with bone-on-bone contact is unlikely to respond meaningfully. Grade II–III disease, with cartilage loss but intact bone surfaces — that is where the evidence is strongest, and where I would consider BMAC as a serious non-surgical option.

Evidence Table — BMAC in Cartilage and Joint Conditions

BMAC in AVN of the Femoral Head — A Condition We See a Lot in India

Avascular necrosis of the femoral head — AVN — is devastatingly common in India, and I say this from years of clinical practice. The causes are well-known: prolonged corticosteroid use (often for rheumatoid arthritis, lupus, or even the aftermath of post-COVID treatment), excessive alcohol consumption, trauma to the hip. India has a particular burden of post-COVID AVN that we are still navigating — a legacy of the heavy steroid protocols used in 2020–2021.

AVN at its core is a problem of blood supply failure to the femoral head. The bone dies, and without intervention, the head collapses. Once collapse occurs, the options narrow sharply to hip replacement. The challenge — and the opportunity — is the pre-collapse stage.

Core decompression with BMAC injection directly into the necrotic lesion is the most evidence-supported joint-preserving strategy for early-stage AVN. The core decompression — drilling a channel into the femoral head — reduces the elevated intraosseous pressure that worsens ischaemia. BMAC then provides the osteogenic (bone-forming) cellular signals and growth factors needed to stimulate revascularisation and bone regeneration within the necrotic zone.

A 2025 prospective study (Medicine Journal, Erciyes et al.) of 22 patients with pre-collapse AVN demonstrated that core decompression with BMAC injection produced meaningful clinical and radiological improvement at 12-month follow-up, with reduced progression rates compared to historical decompression-only data. A 2021 scoping review analysing 612 hips across 11 studies confirmed benefit in precollapse stages in reducing radiological progression and hip replacement rates.

My approach at IBAP Clinics is to combine core decompression with BMAC and often add a biological cocktail — which may include PRP and concentrated growth factors — to maximise the regenerative signal. We use fluoroscopic guidance to target the concentrate precisely into the necrotic zone, not just the decompression track. This precision matters. You are trying to deliver cells to a defined area of ischaemic bone, not flood the joint.

BMAC for Tendons, Ligaments, and Muscles — The Sporting Injuries Dimension

Beyond joints, BMAC has found an increasingly important role in soft-tissue injuries. Tendons, in particular, have poor intrinsic healing capacity — partly because of their limited vascularity, and partly because the mechanical environment of repeated loading prevents the orderly collagen deposition that proper healing requires. Rotator cuff tears, Achilles tendinopathy, lateral epicondylitis, gluteal tendinopathy, patellar tendinopathy — these are conditions where conventional physiotherapy and steroid injections often give partial, temporary relief at best.

BMAC's MSC content can differentiate into tenocytes (tendon cells) under the right biochemical cues. More importantly, the growth factor payload — particularly TGF-β and PDGF — directly stimulates collagen synthesis and tendon matrix remodelling. In a systematic review of BMAC in tendon pathology (PMC5632955), multiple preclinical and early clinical studies confirmed improved tendon integrity and reduced re-tear rates with BMAC augmentation, particularly in rotator cuff repair.

Muscles

For significant muscle tears — Grade II–III hamstring tears in athletes, for example — BMAC injected at the zone of injury provides both anti-inflammatory and regenerative signals. The myogenic differentiation potential of MSCs, combined with the growth factor milieu, can accelerate organised muscle fibre regeneration. Clinical evidence here is less robust than for joints, but the biological rationale is sound, and outcomes in sports medicine practices have been encouraging.

Comparison — BMAC vs PRP vs Steroid for Soft Tissue Conditions

BMAC + PRP — The Combination Approach

I think of BMAC and PRP as complementary rather than competing. PRP — platelet-rich plasma — is rich in growth factors and creates what I call the "landing pad." It activates the local environment, stimulates cell recruitment, and begins the growth factor cascade. BMAC then delivers the cellular reinforcements — the MSCs and progenitor cells that can actually drive structural regeneration.

A 2024 systematic review and meta-analysis (PMC11416799) specifically comparing BMAC alone versus BMAC with PRP in rotator cuff repair found growing interest in the combined modality, though consensus on the optimal protocol has not yet been established. In AVN, BMAC combined with growth factor concentrates — sometimes including PRP — is becoming the standard in leading regenerative centres.

My sequencing preference: PRP is injected at the target site first, either a few minutes before BMAC or simultaneously. The rationale is that PRP degranulates immediately upon activation, flooding the area with growth factors that signal to incoming cells. The BMAC is then delivered into this prepared environment, where its cellular cargo has the optimal conditions to engraft, survive, and function. Think of PRP as preparing the soil and BMAC as planting the seeds.

Who Is a Good Candidate for BMAC?

Patient selection is perhaps the most critical determinant of outcomes with BMAC. The procedure is not appropriate for every patient with joint pain, and setting realistic expectations is as important as the technical execution. These are the patients in whom I find BMAC most rewarding:

Patients with early-to-moderate joint degeneration — OA Grade II–III — who have not responded adequately to physiotherapy, weight management, and oral treatments, and are not yet appropriate for or willing to consider joint replacement. Younger patients — particularly those under 55–60 — where buying five to ten years of reasonable joint function before any surgical conversation is enormously valuable. Patients with AVN of the femoral head at pre-collapse stage (Ficat I–IIb), where BMAC combined with core decompression may genuinely avert hip replacement. Athletes and active individuals with tendon or ligament injuries where the goal is structural healing, not just symptom management. And patients who have already had surgery and are looking for biological augmentation of healing — post-ACL reconstruction, post-rotator cuff repair.

Patients who are not likely to benefit: those with end-stage disease and complete cartilage loss, systemic inflammatory conditions that have not been adequately controlled, active joint infection, malignancy, or bleeding disorders. Haematological bone marrow conditions also preclude harvest.

A Personal Reflection — Why Regenerative Medicine Matters in the Indian Context

I have been practicing pain medicine in Hyderabad for nearly eight years now, having spent the earlier part of my career in the NHS. And one thing strikes me every single week in clinic: the Indian musculoskeletal burden is uniquely heavy, and it is getting worse.

We see young IT professionals — 28, 32 years old — with knee pain from being sedentary at desks for twelve hours a day. We see builders and factory workers whose joints have simply been worn beyond what the human body was designed to endure. We see patients who tried to manage their joint pain with years of NSAIDs and have now added stomach damage to their joint damage. The potholes on the roads, the brutal speeds at which we take those speed breakers, the weight carried on two-wheelers — these are not trivial mechanical stresses on the spine and hips over a lifetime of daily commuting.

And then there is the steroid legacy. So many patients coming to me with AVN or fragility fractures have a history of poorly supervised steroid prescribing — for everything from allergies to back pain. The post-COVID cohort has added substantially to this. These are young patients, often in their 30s and 40s, facing femoral head collapse and the prospect of hip replacement decades too early.

This is the context in which I believe BMAC and regenerative medicine have a genuinely transformative role to play in India. Not as a luxury treatment for the wealthy, but as a serious, evidence-based attempt to give patients their lives back without surgery. The cost remains a barrier — I will not pretend otherwise. But as the evidence strengthens and technology becomes more accessible, the calculus will shift.